JP2016526016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526016A5 JP2016526016A5 JP2016512011A JP2016512011A JP2016526016A5 JP 2016526016 A5 JP2016526016 A5 JP 2016526016A5 JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016526016 A5 JP2016526016 A5 JP 2016526016A5
- Authority
- JP
- Japan
- Prior art keywords
- fgfr1
- medicament according
- medicament
- ecd
- fusion molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 33
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 13
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 13
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 13
- 230000004927 fusion Effects 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 101150016624 fgfr1 gene Proteins 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 230000002018 overexpression Effects 0.000 claims 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 7
- 229930012538 Paclitaxel Natural products 0.000 claims 7
- 190000008236 carboplatin Chemical compound 0.000 claims 7
- 229960004562 carboplatin Drugs 0.000 claims 7
- 229960003668 docetaxel Drugs 0.000 claims 7
- 229960001592 paclitaxel Drugs 0.000 claims 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 7
- 230000004544 DNA amplification Effects 0.000 claims 6
- 210000002230 centromere Anatomy 0.000 claims 3
- 210000000349 chromosome Anatomy 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 2
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 2
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 2
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 claims 2
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 2
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000000018 DNA microarray Methods 0.000 claims 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- -1 at least 5 mg / kg Chemical compound 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 230000003595 spectral effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818220P | 2013-05-01 | 2013-05-01 | |
| US61/818,220 | 2013-05-01 | ||
| US201361831029P | 2013-06-04 | 2013-06-04 | |
| US61/831,029 | 2013-06-04 | ||
| PCT/US2014/036140 WO2014179448A2 (en) | 2013-05-01 | 2014-04-30 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526016A JP2016526016A (ja) | 2016-09-01 |
| JP2016526016A5 true JP2016526016A5 (enExample) | 2017-06-15 |
Family
ID=50928263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512011A Pending JP2016526016A (ja) | 2013-05-01 | 2014-04-30 | がんを治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160067307A1 (enExample) |
| EP (1) | EP2991669A2 (enExample) |
| JP (1) | JP2016526016A (enExample) |
| KR (1) | KR20160003141A (enExample) |
| CN (1) | CN105188732A (enExample) |
| AU (1) | AU2014259956A1 (enExample) |
| BR (1) | BR112015027607A8 (enExample) |
| CA (1) | CA2908391A1 (enExample) |
| HK (1) | HK1213817A1 (enExample) |
| MX (1) | MX2015015115A (enExample) |
| RU (1) | RU2015150233A (enExample) |
| SG (1) | SG11201508878WA (enExample) |
| WO (1) | WO2014179448A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| PE20160190A1 (es) | 2013-08-01 | 2016-04-28 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados |
| KR20180028524A (ko) * | 2015-07-24 | 2018-03-16 | 데비오팜 인터네셔날 에스 에이 | Fgfr 발현 및 fgfr 억제제에 대한 민감성 |
| BR112018010410A8 (pt) * | 2015-11-23 | 2019-02-26 | Five Prime Therapeutics Inc | método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1 |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| AU2018215794A1 (en) * | 2017-02-06 | 2019-07-25 | Fusion Pharmaceuticals Inc. | Methods, compositions, and kits for treatment of cancer |
| WO2018195273A1 (en) * | 2017-04-19 | 2018-10-25 | The Corporation Of Mercer University | Sam-1 protein, composition and methods of use |
| CN110621336B (zh) | 2017-05-16 | 2024-05-14 | 戊瑞治疗有限公司 | 癌症治疗中抗fgfr2抗体与化学治疗剂的组合 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| EP1125584A4 (en) | 1998-10-30 | 2005-01-12 | Takeda Chemical Industries Ltd | PREPARATIONS CONTAINING BETACELLULIN PROTEIN |
| IL151865A0 (en) | 2000-03-31 | 2003-04-10 | Genentech Inc | Compositions and methods for detecting and quantifying gene expression |
| IL152656A0 (en) | 2000-05-19 | 2003-06-24 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US20090105329A1 (en) * | 2005-11-04 | 2009-04-23 | Judy Chiao | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| NZ703786A (en) * | 2010-11-15 | 2016-08-26 | Five Prime Therapeutics Inc | Fgfr1 extracellular domain combination therapies |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CN107823630A (zh) * | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
-
2014
- 2014-04-30 AU AU2014259956A patent/AU2014259956A1/en not_active Abandoned
- 2014-04-30 US US14/785,691 patent/US20160067307A1/en not_active Abandoned
- 2014-04-30 SG SG11201508878WA patent/SG11201508878WA/en unknown
- 2014-04-30 CA CA2908391A patent/CA2908391A1/en not_active Abandoned
- 2014-04-30 CN CN201480024106.3A patent/CN105188732A/zh active Pending
- 2014-04-30 MX MX2015015115A patent/MX2015015115A/es unknown
- 2014-04-30 BR BR112015027607A patent/BR112015027607A8/pt not_active IP Right Cessation
- 2014-04-30 RU RU2015150233A patent/RU2015150233A/ru not_active Application Discontinuation
- 2014-04-30 WO PCT/US2014/036140 patent/WO2014179448A2/en not_active Ceased
- 2014-04-30 JP JP2016512011A patent/JP2016526016A/ja active Pending
- 2014-04-30 KR KR1020157033756A patent/KR20160003141A/ko not_active Withdrawn
- 2014-04-30 EP EP14729530.7A patent/EP2991669A2/en not_active Withdrawn
- 2014-04-30 HK HK16101949.2A patent/HK1213817A1/zh unknown
-
2018
- 2018-01-03 US US15/861,047 patent/US20180280470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526016A5 (enExample) | ||
| Wood et al. | Molecular histology of lung cancer: from targets to treatments | |
| Maksakova et al. | Distinct roles of KAP1, HP1 and G9a/GLP in silencing of the two-cell-specific retrotransposon MERVL in mouse ES cells | |
| Lee et al. | Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers | |
| Memon et al. | The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients | |
| Buss et al. | The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants | |
| Custodio et al. | Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study | |
| JP2015505818A5 (enExample) | ||
| JP2019509739A5 (enExample) | ||
| JP2016169229A5 (enExample) | ||
| Sato et al. | Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel | |
| IL259672B2 (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf | |
| Gorbatenko et al. | ErbB2 upregulates the Na+, HCO3‐‐cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Krüppel‐like factor 4 | |
| Bian et al. | RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments | |
| Sohn et al. | Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer | |
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| Yang et al. | Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy | |
| Zhou et al. | Gene microarray analysis of lncRNA and mRNA expression profiles in patients with hypopharyngeal squamous cell carcinoma | |
| Lee et al. | ERBB2 kinase domain mutation in the lung squamous cell carcinoma | |
| Donaires et al. | E2F transcription factors associated with up-regulated genes in glioblastoma | |
| Aklillu et al. | Frequency of the SLCO1B1 388A> G and the 521T> C polymorphism in Tanzania genotyped by a new LightCycler®-based method | |
| Tian et al. | Microarray expression profile of long non-coding RNAs in paclitaxel-resistant human lung adenocarcinoma cells | |
| Jiang et al. | The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer | |
| Walter et al. | microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma | |
| Galeș et al. | Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging Applications |